Interestingly, we did not observe any significant association between specific KRAS amino acid mutational changes and RAG, suggesting that specific mutations do not drive RAS activity heterogeneity in distinct ways in the context of lung adenocarcinoma (Fig. 3b). The gene discussed is KRAS; the disease is lung adenocarcinoma.